367-06-010 ISMRM Abstract

Deuterium MRI for the Evaluation of Treatment Response in Solid Tumors: Pseudo-progression vs Progression

Primary: Preclinical Animal & in vitro MR - Biology, Models, Methods

Secondary: Contrast Mechanisms - Deuterium

367-06-010 · Advanced Methods in Renal MRI · Monday, 11 May, 5:05 PM–6:00 PM · Digital Posters Row H

Keywords: Deuterium Tumors Pseudoprogression Deuterated water

Accepted

Mingchen He¹, Jill M Duzen², Hunter Reavis³, Steven G Turowski⁴, Joseph A Spernyak⁴, Michael E Feigin³, Aimee Stablewski⁵, Ravi Jasuja⁶, Nataliya P Buxbaum ¹

¹Roswell Park Comprehensive Cancer Center, Buffalo, United States of America

²Pediatrics, Roswell Park Comprehensive Cancer Center, Buffalo, United States of America

³Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, United States of America

⁴Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Buffalo, United States of America

⁵Molecular & Cellular Biology, Roswell Park Comprehensive Cancer Center, Buffalo, United States of America

⁶XYone Therapeutics, United States of America

Presenting Author: Nataliya P Buxbaum

Synopsis

Motivation:

Goals:

Approach:

Results:

Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

References

1. Min, S.J., Jang, H.J. & Kim, J.H. Comparison of the RECIST and PERCIST criteria in solid tumors: a pooled analysis and review. Oncotarget 7, 27848-27854 (2016)

2. Park, H.J., et al. Incidence of Pseudoprogression during Immune Checkpoint Inhibitor Therapy for Solid Tumors: A Systematic Review and Meta-Analysis. Radiology 297, 87-96 (2020)

3. Young, J.S., Al-Adli, N., Scotford, K., Cha, S. & Berger, M.S. Pseudoprogression versus true progression in glioblastoma: what neurosurgeons need to know. J Neurosurg 139, 748-759 (2023)

4. Pires da Silva, I., et al. Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy. Cancer 126, 86-97 (2020).

5. He, M., et al. Deuterium magnetic resonance imaging of tumors after in vivo deuterated water labeling to low total body water levels. ISMRM #3086(2025).

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/367-06-010